DK2419728T3 - Biomarkør til at overvåge patienter - Google Patents

Biomarkør til at overvåge patienter

Info

Publication number
DK2419728T3
DK2419728T3 DK10719285.8T DK10719285T DK2419728T3 DK 2419728 T3 DK2419728 T3 DK 2419728T3 DK 10719285 T DK10719285 T DK 10719285T DK 2419728 T3 DK2419728 T3 DK 2419728T3
Authority
DK
Denmark
Prior art keywords
biomarker
monitor patients
patients
monitor
Prior art date
Application number
DK10719285.8T
Other languages
English (en)
Inventor
Bruce Acres
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK2419728T3 publication Critical patent/DK2419728T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10719285.8T 2009-04-17 2010-04-12 Biomarkør til at overvåge patienter DK2419728T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305328 2009-04-17
PCT/EP2010/054743 WO2010119003A1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients

Publications (1)

Publication Number Publication Date
DK2419728T3 true DK2419728T3 (da) 2014-02-03

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10719285.8T DK2419728T3 (da) 2009-04-17 2010-04-12 Biomarkør til at overvåge patienter

Country Status (27)

Country Link
US (2) US20120058493A1 (da)
EP (1) EP2419728B1 (da)
JP (1) JP5661738B2 (da)
KR (1) KR20120027146A (da)
CN (1) CN102395883B (da)
AU (1) AU2010237215B2 (da)
BR (1) BRPI1010512A2 (da)
CA (1) CA2759050A1 (da)
CO (1) CO6440591A2 (da)
CR (1) CR20110513A (da)
CY (1) CY1114910T1 (da)
DK (1) DK2419728T3 (da)
ES (1) ES2445146T3 (da)
HK (1) HK1163246A1 (da)
HR (1) HRP20140262T1 (da)
IL (1) IL214917A (da)
MX (1) MX2011010920A (da)
NZ (1) NZ594896A (da)
PL (1) PL2419728T3 (da)
PT (1) PT2419728E (da)
RU (1) RU2555340C2 (da)
SG (1) SG175060A1 (da)
SI (1) SI2419728T1 (da)
SM (1) SMT201400046B (da)
TW (1) TWI426270B (da)
WO (1) WO2010119003A1 (da)
ZA (1) ZA201107545B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
WO2019113449A1 (en) * 2017-12-08 2019-06-13 Stc.Unm In vivo imaging of tumor infiltration leukocytes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1998037095A2 (en) 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
DK1147181T3 (da) 1999-02-04 2004-09-20 Geron Corp Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1230378B1 (en) 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20040133243A1 (en) 2002-07-26 2004-07-08 Santamore William P. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
PT1896051E (pt) * 2005-06-28 2015-01-13 Oncothyreon Inc Método de tratamento de pacientes com uma vacina de glicoproteína mucinosa (muc-1)
CN101541342A (zh) * 2006-12-05 2009-09-23 特朗斯吉有限公司 产生提高的免疫应答的手段和方法
CN102046196B (zh) * 2008-05-29 2014-07-30 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法

Also Published As

Publication number Publication date
US20140141039A1 (en) 2014-05-22
TWI426270B (zh) 2014-02-11
MX2011010920A (es) 2011-11-04
PL2419728T3 (pl) 2014-05-30
SMT201400046B (it) 2014-05-07
EP2419728A1 (en) 2012-02-22
RU2011146419A (ru) 2013-05-27
HK1163246A1 (en) 2012-09-07
AU2010237215A1 (en) 2011-09-22
IL214917A0 (en) 2011-11-30
PT2419728E (pt) 2014-03-12
CA2759050A1 (en) 2010-10-21
SG175060A1 (en) 2011-11-28
CN102395883B (zh) 2015-12-02
AU2010237215B2 (en) 2014-05-01
CN102395883A (zh) 2012-03-28
EP2419728B1 (en) 2014-01-08
JP2012524248A (ja) 2012-10-11
IL214917A (en) 2016-03-31
CY1114910T1 (el) 2016-12-14
CR20110513A (es) 2012-01-06
KR20120027146A (ko) 2012-03-21
ZA201107545B (en) 2012-07-25
HRP20140262T1 (hr) 2014-04-25
RU2555340C2 (ru) 2015-07-10
ES2445146T3 (es) 2014-02-28
BRPI1010512A2 (pt) 2016-03-15
SI2419728T1 (sl) 2014-03-31
NZ594896A (en) 2013-07-26
JP5661738B2 (ja) 2015-01-28
US20120058493A1 (en) 2012-03-08
WO2010119003A1 (en) 2010-10-21
CO6440591A2 (es) 2012-05-15
TW201040530A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
DK2646647T3 (da) Frakturkarakterisering
BRPI1009197A2 (pt) preparação de ácido alfa-cetopimélico
DE102009035941B8 (de) Diagnostiksystem
BR112012000657A2 (pt) novos azabicilohexanos
DK2564396T3 (da) Fremgangsmåde til isotop-fremstilling
DE112010000740A5 (de) Endoskop
DK2451354T3 (da) Lancet
DE112011103919A5 (de) Endoskop
DK2453858T3 (da) Fremgangsmåde
BR112013009525A2 (pt) unidade de descompressão
FI20095452A0 (fi) Uudet haaraiset sokerianalyysit
DK2590565T3 (da) Blodprøvetagning
ITPD20090053U1 (it) Paradordi per banchine
DK2419728T3 (da) Biomarkør til at overvåge patienter
DK2459031T3 (da) Barneseng
FI20096190A (fi) Tutkimuslaite
SE0900379L (sv) Benstöd
BR112012002283A2 (pt) monitor de pressao sanguineo
FI20095315A (fi) Iskulaite
IT1395933B1 (it) Sanitario
ES1070798Y (es) Ataud
IT1393297B1 (it) Disposizione funeraria
FR2956571B1 (fr) Structure de lit relevable
ES1073644Y (es) Estructura de colchon
BRPI0924006A2 (pt) estrutura